Stock TKD TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Takeda Pharmaceutical Company Limited Börse Stuttgart

Equities

TKD

JP3463000004

Real-time Estimate Tradegate
Other stock markets
 11:42:23 25/06/2024 am IST 		5-day change 1st Jan Change
24.41 EUR +2.95% Intraday chart for Takeda Pharmaceutical Company Limited -3.34% -8.17%
24/06 Hutchmed China notes Takeda obtains EU approval for Fruzaqla AN
24/06 Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hutchmed China notes Takeda obtains EU approval for Fruzaqla
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
Les sorcières épouvantent l'IA
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes
En Direct des Marchés : LVMH, Accor, Alstom, Atos, Casino, Plastivaloire, Boeing, Geberit...
Borsa di Italia: Le streghe terrorizzano l'AI
Bolsa de Madrid: Las brujas aterrorizan a la IA
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India
Takeda présente au congrès annuel de la PNS des données à long terme de l’essai clinique ADVANCE-CIDP 3 de Phase 3 portant sur l’administration de HYQVIA® à des patients atteints de polyradiculonévrite inflammatoire démyélinisante chronique (PIDC)
Takeda presenta datos de largo plazo del ensayo clínico de fase 3 ADVANCE-CIDP 3 de HYQVIA® en pacientes con polineuropatía desmielinizante inflamatoria crónica (PDIC) en la Reunión Anual de la PNS
Takeda präsentiert Langzeitdaten der klinischen Phase-3-Studie ADVANCE-CIDP 3 mit HYQVIA® bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP) auf der PNS-Jahrestagung
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. TKD Stock
  5. News Takeda Pharmaceutical Company Limited
  6. Other languages